Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS)
CNY 10.84
(0.18%)
CNY 10.84
(0.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 310.08 Million CNY | -35.55% |
| 2022 | 444.31 Million CNY | 121.75% |
| 2021 | 187.54 Million CNY | 17.5% |
| 2020 | 156.25 Million CNY | 1.34% |
| 2019 | 170.68 Million CNY | 15.38% |
| 2018 | 141.75 Million CNY | 13.1% |
| 2017 | 122.14 Million CNY | 8.97% |
| 2016 | 121.1 Million CNY | -6.67% |
| 2015 | 121.89 Million CNY | 15.83% |
| 2014 | 111.48 Million CNY | 10.91% |
| 2013 | 99.26 Million CNY | 14.68% |
| 2012 | 89.83 Million CNY | 24.34% |
| 2011 | 73.07 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 88.21 Million CNY | 47.79% |
| 2024 Q2 | 85.12 Million CNY | -14.5% |
| 2024 Q3 | 100.28 Million CNY | 9.39% |
| 2023 Q3 | 42.94 Million CNY | -24.51% |
| 2023 Q1 | 70.83 Million CNY | -5.6% |
| 2023 Q2 | 56.89 Million CNY | -19.68% |
| 2023 FY | - CNY | -35.55% |
| 2023 Q4 | 46.78 Million CNY | 8.95% |
| 2022 FY | - CNY | 121.75% |
| 2022 Q4 | 75.03 Million CNY | -65.95% |
| 2022 Q3 | 220.36 Million CNY | 531.9% |
| 2022 Q2 | 34.87 Million CNY | -20.73% |
| 2022 Q1 | 43.99 Million CNY | 43.06% |
| 2021 FY | - CNY | 17.5% |
| 2021 Q2 | 29.91 Million CNY | -14.57% |
| 2021 Q4 | 30.75 Million CNY | 2.37% |
| 2021 Q3 | 30.04 Million CNY | 0.41% |
| 2021 Q1 | 35.02 Million CNY | 70.57% |
| 2020 Q3 | 29.82 Million CNY | 11.1% |
| 2020 Q2 | 26.84 Million CNY | 3.07% |
| 2020 Q1 | 26.04 Million CNY | 161.69% |
| 2020 FY | - CNY | 1.34% |
| 2020 Q4 | 20.53 Million CNY | -31.15% |
| 2019 FY | - CNY | 15.38% |
| 2019 Q1 | 34.9 Million CNY | 207.18% |
| 2019 Q2 | 45.83 Million CNY | 31.32% |
| 2019 Q3 | 28.07 Million CNY | -38.75% |
| 2019 Q4 | 9.95 Million CNY | -64.55% |
| 2018 Q2 | 31.25 Million CNY | -10.93% |
| 2018 FY | - CNY | 13.1% |
| 2018 Q4 | 11.36 Million CNY | -57.51% |
| 2018 Q3 | 26.74 Million CNY | -14.42% |
| 2018 Q1 | 35.08 Million CNY | 374.89% |
| 2017 Q2 | 32.74 Million CNY | 15.94% |
| 2017 Q3 | 44.29 Million CNY | 35.27% |
| 2017 Q4 | -12.76 Million CNY | -128.82% |
| 2017 FY | - CNY | 8.97% |
| 2017 Q1 | 28.24 Million CNY | -3.58% |
| 2016 Q4 | 29.28 Million CNY | 21.23% |
| 2016 Q3 | 24.15 Million CNY | 15.14% |
| 2016 FY | - CNY | -6.67% |
| 2016 Q1 | 18.74 Million CNY | -2.63% |
| 2016 Q2 | 20.98 Million CNY | 11.97% |
| 2015 Q2 | 36.67 Million CNY | 29.69% |
| 2015 Q1 | 28.27 Million CNY | 50.64% |
| 2015 FY | - CNY | 15.83% |
| 2015 Q4 | 19.24 Million CNY | -23.4% |
| 2015 Q3 | 25.12 Million CNY | -31.47% |
| 2014 Q3 | 27.31 Million CNY | -23.79% |
| 2014 Q1 | 14.24 Million CNY | -37.15% |
| 2014 FY | - CNY | 10.91% |
| 2014 Q2 | 35.83 Million CNY | 151.54% |
| 2014 Q4 | 18.77 Million CNY | -31.27% |
| 2013 Q4 | 22.66 Million CNY | -5.1% |
| 2013 Q3 | 23.88 Million CNY | 0.0% |
| 2013 FY | - CNY | 14.68% |
| 2012 FY | - CNY | 24.34% |
| 2011 FY | - CNY | 0.0% |